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Abstract
Some natural acetogenins are the most potent inhibitors of bovine heart mitochondrial complex I. These compounds are
characterized by two functional units (i.e. hydroxylated tetrahydrofuran (THF) and K,L-unsaturated Q-lactone ring moieties)
separated by a long alkyl spacer. To elucidate which structural factors of acetogenins including their active conformation are
crucial for the potent inhibitory effect, we synthesized a series of novel acetogenin analogues possessing bis-THF rings. The
present study clearly demonstrated that the natural Q-lactone ring is not crucial for the potent inhibition, although this moiety
is the most common structural unit among a large number of natural acetogenins and has been suggested to be the only
reactive species that directly interacts with the enzyme (Shimada et al., Biochemistry 37 (1998) 854^866). The presence of free
hydroxy group(s) in the adjacent bis-THF rings was favorable, but not essential, for the potent activity. This was probably
because high polarity (or hydrophilicity), rather than hydrogen bond-donating ability, around the bis-THF rings is required
to retain the inhibitor in the active conformation. Interestingly, length of the alkyl spacer proved to be a very important
structural factor for the potent activity, the optimal length being approximately 13 carbon atoms. The present study provided
further strong evidence for the previous proposal (Kuwabara et al., Eur. J. Biochem. 267 (2000) 2538^2546) that the Q-lactone
and THF ring moieties act in a cooperative manner on complex I with the support of some specific conformation of the
spacer. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Acetogenins have very potent and diverse biologi-
cal e¡ects including cytotoxic, antitumor, antimalar-
ial, pesticidal and antifeedant activities [1^5]. In par-
ticular, the inhibitory e¡ect of acetogenins on
mitochondrial NADH-ubiquinone oxidoreductase
(complex I) is worthy of note since the diverse bio-
logical activities are thought to be attributable to this
e¡ect [1,4^7]. In fact, some of these compounds, such
as bullatacin ( = rolliniastatin-2, Fig. 1) and rollinia-
statin-1, are the most potent inhibitors of the enzyme
identi¢ed to date [5,7,8]. Although the acetogenins
act at the terminal electron transfer step of complex
I (i.e. between Fe^S cluster 2 and the ubiquinone
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pool) similarly to the ordinary complex I inhibitors
[8,9], there are few structural similarities between the
acetogenins and ordinary complex I inhibitors such
as piericidin A and rotenone.
The acetogenins are characterized by two function-
al units, the hydroxylated tetrahydrofuran (THF)
and the K,L-unsaturated Q-lactone ring, separated
by a long alkyl chain, although the two units could
each play signi¢cant roles in binding interactions
with the enzyme. Thus, considering their unusual
structural characteristics as well as the very strong
inhibitory potency of acetogenins, detailed analysis
of the inhibitory actions of these inhibitors is impor-
tant to elucidate the structural and functional fea-
tures of the terminal electron transfer step of com-
plex I. As the ¢rst step toward this purpose,
identi¢cation of the crucial structural factors of
acetogenins, including the active conformation re-
quired for their potent inhibitory e¡ects would be
very useful. However, such information is limited
at present.
In a previous study using bis-acetogenin mimics
possessing two Q-lactone rings per inhibitor molecule
[10], we showed that: (1) stereochemistry of the
Q-lactone and the THF ring moieties is not an essen-
tial structural factor for the potent activity; (2) one
molecule of bis-acetogenin does not function as two
reactive inhibitors; and (3) acetogenin acts as a po-
tent inhibitor only when the Q-lactone and the THF
ring moieties are directly linked by an alkyl spacer.
On the basis of these results, we proposed that the
Q-lactone ring is not the only reactive species directly
interacting to the enzyme and that both ring moieties
act in a cooperative manner on the enzyme with the
support of some speci¢c conformation of the spacer,
which may hold the two functional units in the opti-
mal spatial position. Although we used bis-acetoge-
nin mimics in the previous study because of their
ease of synthesis, interpretation of the structural de-
pendency of the variation in their inhibitory activities
is complex due to the presence of two Q-lactone rings
per inhibitor molecule. Therefore, to further extend
our previous work, we newly synthesized natural ace-
togenin-type asymmetrical acetogenin derivatives
(Fig. 1) in which compound structures were system-
atically modi¢ed. The present study demonstrated,
for the ¢rst time, that there is an optimal length of
the alkyl spacer, i.e. approximately 13 carbon atoms.
Our results provided not only strong evidence for the
previous proposal, but also useful guiding principles
for further wide structural modi¢cations with the aim
of developing practical agents.
2. Materials and methods
2.1. Materials
Diepomuricanin (Fig. 1) was synthesized by Kon-
no et al. [11]. Bullatacin was a generous gift from Dr.
Jerry McLaughlin (Purdue University, USA). Pierici-
din A was generously provided by Dr. Shigeo Yosh-
ida (The Institute of Physical and Chemical Re-
search, Japan). Other chemicals were commercial
products of analytical grade.
2.2. Synthesis
Optical rotation was measured with a JASCO
DIP-370 spectrometer. 1H-NMR spectra were taken
with a Burker AC300 (300 MHz) spectrometer. MS
spectra were recorded with a JEOL JMS-700.
For compounds II-B^II-F, introduction of the al-
kyl spacer into the lactone ring moiety, Pd(0)-cata-
lyzed cross-coupling reaction of the THF ring moiety
with the spacer moiety (plus lactone ring), hydroge-
nation of the resultant eneyne intermediates, and ¢-
nal thermal elimination of the phenylsulfanyl group
from the lactone ring were performed by the methods
used for the synthesis of compound II-A (i.e. com-
pound B in [10]). Therefore, we describe here the
synthetic methods only for the fragments that were
modi¢ed from compound II-A. All ¢nal products
were puri¢ed by reverse phase HPLC using Wako-
sil-II 5C18HG (20U250 mm) and methanol (100%)
as an eluent with monitoring at 220 nm.
2.2.1. Compound II-B
The lactone ring, 2-(phenylthio)-Q-butyrolactone,
was synthesized by adding phenyl disul¢de (1.1 eq.)
to Q-butyrolactone in the presence of lithium diiso-
propylamide (LDA) in THF at 378‡C. Compound
II-B: 1H-NMR (300 MHz, CDCl3) N 7.09 (m, 1H),
4.78^4.76 (m, 2H), 3.92^3.80 (m, 4H), 3.42^3.36 (m,
2H), 2.43 (br s, 2H), 2.32^2.26 (m, 2H), 2.02^1.92
(m, 4H), 1.73^1.20 (m and br s, 44H), 0.88 (t,
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J = 6.7 Hz, 3H). HRMS (FAB): calculated for
C36H64O6Na [M+Na] 615.4601, found 615.4621.
2.2.2. Compound II-C
(5S)-5-Methyl-2-(phenylthio)-N-valerolactone (1)
was synthesized starting from commercially available
(S)-propyleneoxide by 8 reaction steps, as shown in
Fig. 2 (Scheme 1) [12]. Compound II-C: 1H-NMR
(300 MHz, CDCl3) N 6.52 (m, 1H), 4.55^4.45 (m,
1H), 3.90^3.80 (m, 4H), 3.49^3.35 (m, 2H), 2.39^
2.27 (m, 3H), 2.25^2.13 (m, 1H), 2.00^1.93 (m,
4H), 1.42 (d, J = 6.3 Hz, 3H), 1.80^1.20 (m and br
s, 44H), 0.88 (t, J = 6.8 Hz, 3H). HRMS (FAB):
calculated for C38H69O6 [M+H] 621.5094, found
621.5142.
2.2.3. Compound II-D
(S)-(3)-1,2-Epoxyhexane (2) was obtained in
s 99% ee by the hydrolytic kinetic resolution of com-
mercially available racemic 1,2-epoxyhexane using
chiral cobalt(salen) complex [13]: [K]rtD =315.8‡
(neat). The purity was determined by gas chromatog-
raphy. The lactone ring was prepared from phenyl-
thioacetic acid and (S)-1,2-epoxyhexane in the pres-
ence of LDA in THF at 378‡C, as shown in Fig. 2
(Scheme 2). Compound II-D: 1H-NMR (300 MHz,
CDCl3) N 6.99 (m, 1H), 4.92^4.86 (m, 1H), 3.89^3.80
(m, 4H), 3.40^3.35 (m, 2H), 2.29^2.24 (m, 2H), 2.00^
1.93 (m, 4H), 1.76^1.19 (m and br s, 50H), 0.91 (t,
J = 6.6 Hz, 3H), 0.88 (t, J = 6.5 Hz, 3H). HRMS
(FAB): calculated for C40H73O6 [M+H] 649.5407,
found 649.5324.
2.2.4. Compounds II-E and II-F
Alkyl spacers of compounds II-E and II-F (i.e.
(E,Z)-1,12-diiodo-1-dodecene and (E,Z)-1,15-diiodo-
1-pentadecene, respectively) were synthesized by 8
reaction steps, as shown in Fig. 2 (Scheme 3), taking
the former as an example [14]. For (E,Z)-1,15-diio-
do-1-pentadecene, dodecyl bromide was used in place
of nonyl bromide in reaction step l. Introduction of
spacers into (4S)-4-methyl-2-(phenylthio)-Q-butyro-
lactone was carried out by the previously reported
method [10]. Compound II-E: 1H-NMR (300 MHz,
CDCl3) N 6.98 (m, 1H), 5.00 (dq, J = 7.0, 1.5 Hz,
1H), 3.89^3.80 (m, 4H), 3.42^3.36 (m, 2H), 2.29^
2.23 (m, 2H), 2.00^1.93 (m, 4H), 1.41 (d, J = 6.3
Hz, 3H), 1.76^1.20 (m and br s, 50H), 0.88 (t,
J = 6.8 Hz, 3H). HRMS (FAB): calculated for
C40H73O6 [M+H] 649.5407, found 649.5462. Com-
pound II-F: 1H-NMR (300 MHz, CDCl3) N 6.98 (m,
1H), 5.00 (dq, J = 7.0, 1.5 Hz, 1H), 3.89^3.80 (m,
4H), 3.42^3.36 (m, 2H), 2.29^2.23 (m, 2H), 2.00^
1.93 (m, 4H), 1.41 (d, J = 6.3 Hz, 3H), 1.76^1.20 (m
and br s, 56H), 0.88 (t, J = 6.8 Hz, 3H). HRMS
(FAB): calculated for C43H78O6Na [M+Na]
713.5696, found 713.5570.
2.2.5. Compound II-G
The key intermediate 7 was synthesized as shown
in Fig. 2 (Scheme 4). Intermediate 4 was synthesized
by 5 reaction steps from intermediate 3, which was
prepared by the previously reported method [10]. In-
termediate 4 was protected with chloromethyl methyl
ether in the presence of N,N-diisopropylethylamine
in CH2Cl2 at 0‡C to a¡ord 5. Nucleophilic epoxide
opening of 5 by lithium (trimethylsilyl)acetylide in
the presence of BF3/Et2O in THF at 378‡C, fol-
lowed by desilylation with tetrabutylammonium £u-
oride in THF at 0‡C produced alkyne 6. Acetylation
of free alcohol by acetyl chloride in the presence of
N,N-dimethylaminopyridine in CH2Cl2 at 0‡C pro-
duced intermediate 7. Pd(0)- and CuI-catalyzed
cross-coupling reaction of 7 with (E,Z,3RS,5S)-3-
(9Q-iodonon-8-enyl)-5-methyl-3-(phenylthio)tetrahy-
drofuran-2-one, which was synthesized by the previ-
ously reported method [10], a¡orded the eneyne in-
termediate 8. The ¢nal product was prepared from 8
by three reaction steps as described previously [10].
Compound II-G: 1H-NMR (300 MHz, CDCl3) N
6.99 (m, 1H), 5.00 (dq, J = 1.5, 7.0 Hz, 1H), 4.85
(m, 1H), 4.02 (m, 1H), 3.90 (m, 2H), 3.80 (m, 1H),
3.37 (m, 1H), 2.44 (m, 1H), 2.29^2.23 (m, 2H), 2.08
(s, 3H), 2.01^1.90 (m, 4H), 1.78^1.68 (m, 2H), 1.66^
1.20 (m, 40H), 1.41 (d, J = 7.0 Hz, 3H), 0.88 (t,
J = 6.8 Hz, 3H). HRMS (FAB): calculated for
C39H69O7 [M+H] 649.5043, found 649.5073.
2.2.6. Compound II-H
Compound II-H was obtained by acetylation of
compound II-G by acetyl chloride in pyridine and
N,N-diethylaniline at room temperature. 1H-NMR
(300 MHz, CDCl3) N 6.99 (m, 1H), 5.00 (dq,
J = 1.5, 7.0 Hz, 1H), 4.85 (m, 2H), 4.00 (m, 2H),
3.91 (m, 2H), 2.29^2.23 (m, 2H), 2.07 (s, 6H), 2.04^
1.96 (m, 4H), 1.73^1.63 (m, 2H), 1.62^1.20 (m, 40H),
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1.41 (d, J = 7.0 Hz, 3H), 0.87 (t, J = 6.8 Hz, 3H).
HRMS (FAB): calculated for C41H71O8 [M+H]
691.5149, found 691.5014.
2.3. Assays
Bovine heart submitochondrial particles (SMP)
were prepared by the method of Matsuno-Yagi and
Hate¢ [15] using a sonication medium containing
0.25 M sucrose, 1 mM succinate, 1.5 mM ATP,
10 mM MgCl2, 10 mM MnCl2 and 10 mM Tris^
HCl (pH 7.4), and stored in a bu¡er containing
0.25 M sucrose and 10 mM Tris^HCl (pH 7.4) at
378‡C.
The NADH oxidase activity in SMP was followed
spectrometrically with a Shimadzu UV-3000 (340
nm, O= 6.2 mM31 cm31) at 30‡C. The reaction me-
dium (2.5 ml) contained 0.25 M sucrose, 1 mM
MgCl2 and 50 mM phosphate bu¡er (pH 7.4). The
¢nal mitochondrial protein concentration was 30 Wg
of protein/ml. The reaction was started by adding
50 WM NADH after equilibration of SMP with in-
hibitor for 5 min.
For some test compounds, the inhibition of
NADH-Q1 oxidoreductase activity in SMP was also
determined following NADH oxidation at 30‡C in
the same reaction medium in the presence of 50 WM
Q1, 0.2 WM antimycin A, 0.2 WM MOA-stilbene and
2 mM KCN. Since structural dependency of the in-
hibitory potencies in NADH-Q1 oxidoreductase as-
say was comparable to that in NADH oxidase assay,
the results of the former are not shown in Table 1.
3. Results and discussion
3.1. Roles of Q-lactone ring in the inhibitory action
Based on the results of 1H-NMR spectroscopic
and di¡erential scanning calorimetry studies of ace-
Fig. 1. Structure of bullatacin ( = rolliniastatin-2) and acetogenin analogues synthesized in this study.
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togenins in liposomal membranes, McLaughlin and
colleagues [16] proposed a model of active conforma-
tion of these inhibitors in the membrane environ-
ment; wherein the THF ring with £anking hydroxy
(OH) groups reside near the glycerol backbone of
phosphatidylcholine irrespective of the number of
THF ring and act as hydrophilic anchors at the
membrane surface, while the Q-lactone ring directly
interacts with the target site of complex I (probably
the ubiquinone reduction site, [8,9]) by lateral di¡u-
sion in the mitochondrial membrane interior. This
proposed crucial role of the Q-lactone moiety is con-
sistent with the observation that almost all potent
natural acetogenins as inhibitors of complex I pos-
sess an K,L-unsaturated Q-lactone ring.
If this model is true, the Q-lactone ring may be
regarded as the only reactive species directly interact-
ing to the enzyme, and hence chemical modi¢cation
of this moiety is expected to result in a decrease in
the inhibitory potency by several orders of magni-
tude. However, the previous ¢nding that (R)-deriva-
tive of bis-acetogenin, in which the Q-methyl group
on the lactone ring is in the R-con¢guration in con-
trast to the S-con¢guration of natural products (cf.
Fig. 1), shows an inhibitory e¡ect as potent as that of
the (S)-derivative [10] suggested that natural K,L-un-
saturated Q-lactone itself may not be crucial for the
activity.
To obtain further information regarding the role
of Q-lactone ring moiety, we synthesized compounds
II-A^II-D. Compound II-A was the standard com-
pound used to evaluate the e¡ects of structural mod-
i¢cations throughout this study. Since the 4-OH
group of bullatacin is not an essential structural fac-
tor [5,10], we deleted this unit to facilitate synthesis.
In addition, although natural acetogenins possessing
bis-THF rings with £anking OH groups have various
stereochemical arrangements surrounding this moi-
ety, we ¢xed the con¢guration as threo/trans/threo/
trans/threo (i.e. asimicin-type con¢guration, [1]).
Compound II-B exhibited inhibition as potent as
that of compound II-A, indicating that the presence
of a Q-methyl group is not crucial for the potent
activity. This was reasonable since the stereochemis-
try of the Q-methyl group is not important for the
activity [10], as mentioned above. This and the ob-
servation that the N-lactone derivative (compound II-
C) retained very potent activity clearly showed that
natural Q-lactone ring is not crucial for the activity,
although this unit is one of the most common struc-
tural features of natural acetogenins [1]1. The bulky
n-butyl derivative (compound II-D) retained fairly
potent activity, indicating that steric hindrance
around the Q-lactone ring does not severely interfere
with inhibitor binding to the enzyme. These results
strongly suggested that recognition of the Q-lactone
ring moiety by the enzyme is fairly loose. On the
basis of these ¢ndings along with the previous results
[10], we concluded that the natural K,L-unsaturated
Q-lactone ring is not the only reactive species directly
interacting with the enzyme. The loose recognition of
inhibitor structure by the enzyme may be associated
with the proposed large cavity-like structure of the
inhibitor (or ubiquinone) binding domain in complex
I [8,9,17^19].
3.2. Roles of alkyl spacer in the inhibitory action
The Q-lactone ring is connected to the THF ring
moiety by a £exible alkyl spacer. The most common
spacer size of potent natural acetogenins is 13 carbon
Table 1
Summary of inhibitory potencies of test compounds
Inhibitors I50 (nM)
Bullatacin ( = Rolliniastatin-2) 1.2 þ 0.2
Compound II-A 1.3 þ 0.2
Compound II-B 1.2 þ 0.1
Compound II-C 1.3 þ 0.1
Compound II-D 7.5 þ 0.5
Compound II-E 15 þ 3
Compound II-F 260 þ 25
Compound II-G 2.1 þ 0.3
Compound II-H 7.2 þ 0.6
Diepomuricanin 2800 þ 300
Piericidin A 2.3 þ 0.3
The I50 values are the molar concentrations needed to halve the
control NADH oxidase activity and were obtained from three
independent experiments. The ¢nal mitochondrial protein con-
centration was 30 Wg of protein/ml. The control enzyme activity
was 0.55^0.65 Wmol NADH/min/mg of protein. Compound II-
A is the same inhibitor as compound B in [10]
1 This idea does not deny an important role of the lactone ring
moiety in the inhibitory action. The presence of a polar lactone
ring at one end of the inhibitor molecule is important for the
inhibition since it would act on the enzyme in a cooperative
manner with the THF ring moiety, as discussed latter.
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atoms [1,5]. Using natural and synthetic bis-acetoge-
nin analogues with spacers of di¡erent lengths, we
previously demonstrated that shortening of the
spacer from 13 carbons results in a decrease in in-
hibitory potency, as shown in Fig. 3 with natural
products as examples [5,10]. In addition, we have
shown that acetogenin acts as a potent inhibitor
only when the Q-lactone and the THF ring moieties
are directly linked by a £exible alkyl spacer [10].
These ¢ndings revealed an important role of the al-
kyl spacer in the inhibitory action. However, since
the e¡ect of extension of the spacer has not been
examined to date, it is still unknown whether there
is an optimal spacer length for exhibiting the potent
Fig. 2. a, n-BuLi, (trimethylsilyl)acetylene, THF, hexamethylphosphoramide, 378‡C; b, 3,4-dihydro-2H-pyran, p-toluenesulfonic acid,
CH2Cl2 ; c, (n-Bu)4NF, THF; d, n-BuLi, ClCOOMe, THF, 378‡C to rt; e, H2, Pd/C, EtOAc; f, lithium diisopropylamide, (PhS)2,
THF, 378‡C to rt; g, p-toluenesulfonic acid, MeOH; h, (i) NaOH, MeOH, H2O, re£ux, (ii) p-toluenesulfonic acid (2 mol%), benzene,
re£ux; i, 0.5 mol% (salen)Co(OAc) complex, 0.55 eq. H2O; j, PhSCH2COOH, lithium diisopropylamide, THF, 378‡C; k, p-toluene-
sulfonic acid (2 mol%), benzene, re£ux; l, n-BuLi, CH3(CH2)8Br, THF, 78‡C; m, potassium 3-aminopropylamide, H2N(CH2)3NH2 ;
n, tert-butyldimethylsilyl chloride, imidazole, DMF; o, (i) n-Bu3SnH, 2,2P-azobisisobutyronitrile, 130‡C, (ii) I2, ether, rt ; p, (i) mesyl
chloride, Et3N, THF, 0‡C, (ii) NaI, acetone; q, (4S)-4-methyl-2-(phenylthio)-Q-butyrolactone, sodium bis(trimethylsilyl)amide, THF,
hexamethylphosphoramide, 0‡C; r, chloromethyl methyl ether, N,N-diisopropylethylamine, CH2Cl2, 0‡C; s, n-BuLi, (trimethylsilyl)ace-
tylene, BF3/Et2O, THF, 378‡C, t, (n-Bu)4NF, THF, 0‡C; u, acetyl chloride, N,N-dimethylaminopyridine, CH2Cl2, 0‡C to rt;
v, (E,Z,3RS,5S)-3-(9Q-iodonon-8-enyl)-5-methyl-3-(phenylthio)tetrahydrofuran-2-one, Pd(PPh3)4, Et3N, CuI; w, acetyl chloride, N,N-di-
ethylaniline, pyridine.
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activity. This is important not only to elucidate the
functional role of the spacer, but also to obtain use-
ful information for further wide structural modi¢ca-
tions of acetogenins. We therefore synthesized com-
pounds II-E and II-F, which have spacers of 16 and
19 carbon atoms, respectively, and compared their
activities with that of compound II-A possessing a
spacer of 13 carbon atoms.
As shown in Table 1 and Fig. 3, the longer the
length of the spacer, the weaker the potency became.
Compound II-F is one of the weakest inhibitors
among the wide variety of acetogenins examined to
date [5,7,9,10,20,21]. Taking into consideration the
markedly poor activity of murihexocin ( I50 = 330
nM, [5]), which possesses two additional OH groups
in its spacer region, it is noteworthy that structural
modi¢cations of the spacer moiety, rather than the
Q-lactone and the THF ring moieties, drastically af-
fected the inhibitory potency. Together with the pre-
vious results [5,10], we concluded that the optimal
length of the spacer is approximately 13 carbon
atoms, although extension of the spacer has a
much greater negative e¡ect on the activity than
shortening (Fig. 3). Interestingly, the most potent
natural acetogenins, such as bullatacin ( = rolliniasta-
tin-2) and rolliniastatin-1 have the optimal spacer
length. The length of the spacer may be closely asso-
ciated to an active conformation of the spacer itself,
which, in turn, may govern some optimal spatial po-
sitioning of the Q-lactone and THF ring moieties in
the enzyme. Design syntheses of acetogenins, in
which the spatial positions of the two ring moieties
are ¢xed to each other in di¡erent manners by spe-
ci¢c structures of the spacer, might be helpful to elu-
cidate the active conformation of the acetogenin mol-
ecule.
3.3. Roles of OH groups in the adjacent THF rings in
the inhibitory action
The presence of OH group(s) in the adjacent THF
ring(s) is also a common structural feature of natural
acetogenins [1]. We previously examined the e¡ects
of acetylation of the OH group(s) using bis-acetoge-
nins, while interpretation of the results is somewhat
complicated since mono-acetylated bis-acetogenin
(i.e. compound J in [10]) still has a free OH group
located on the side of the other Q-lactone ring. To
discriminate between the roles of the two OH groups
in asymmetrical acetogenin, we performed selective
acetylation of one of the two OH groups of com-
pound II-A. Selective acetylation of the OH group
located on the side of Q-lactone ring was successfully
carried out as shown in Fig. 2 (Scheme 4), whereas
that of the OH group located on the side of the alkyl
tail was unsuccessful. Therefore, we next tried to
Fig. 3. E¡ect of length of the alkyl spacer on the inhibitory po-
tency. The number of carbon atoms in the spacers of bullata-
cin, parvi£orin and longimicin C are 13, 11 and 7, respectively.
Those of compounds II-E and II-F are 16 and 19, respectively.
The optimal length of the spacer was approximately 13 carbon
atoms.
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separate two mono-acetylated derivatives of com-
pound II-A from their mixture prepared by direct
acetylation of compound II-A. However, separation
was unsuccessful due to identical chromatographic
properties of the two isomers. Therefore, we exam-
ined the roles of the OH groups using compounds II-
G and II-H as follows.
Acetylation of the OH group located on the side of
Q-lactone ring resulted in a slight decrease in the in-
hibitory potency (compounds II-G vs. II-A). This
result was consistent with the observation that mur-
icatetrocin B, which possesses only one £anking OH
on the side of the alkyl tail, has an inhibitory e¡ect
as potent as that of bullatacin (I50 = 1.5 nM, [5]). On
the other hand, the inhibitory potency was consider-
ably decreased by acetylation of both OH groups
(compounds II-H vs. II-A). These observations indi-
cated that although neither the number of THF rings
nor the stereochemistry surrounding the THF ring(s)
with £anking OH groups are crucial structural fac-
tors [5,7,10,20], the presence of free OH groups is
favorable, but not crucial, for the potent inhibitory
e¡ect. Nevertheless, judging from the extent of de-
crease in the potencies, it is unlikely that either of the
two OH groups alone is de¢nitely important for the
inhibitory action.
On the other hand, the observation that com-
pound II-H and di-acetylated bis-acetogenin (com-
pound K in [10]) completely inhibited complex I ac-
tivity at far less than WM order suggests that high
polarity (or hydrophilicity) around the THF ring
moiety, rather than the hydrogen bond-donating
ability of the OH groups, would be required to retain
an active conformation of the inhibitor2. This was
supported by the marked loss of inhibitory activity
of diepomuricanin (Fig. 1), which has no polar sub-
stituent around the epoxy groups located in the mid-
dle of the inhibitor3. Importance of the high polarity
around the THF ring moiety may explain why both
the number of THF rings and the stereochemistry
surrounding hydroxylated THF ring moiety are not
essential structural factors for the potent inhibitory
e¡ect. Furthermore, from a molecular viewpoint, the
importance of high polarity may be associated with
the fact that the putative target subunit of acetogenin
in bovine complex I (PSST, [22]) is hydrophilic and
contains no transmembrane helices according to sec-
ondary structure prediction [23^25].
As a prerequisite for the conformational model of
McLaughlin and colleagues [16], they noted a signi¢-
cant contribution of the intermolecular hydrogen
bonds between the OH groups in the adjacent THF
rings and the oxygen atoms in the glycerol backbone
of the phospholipid when the bis-THF rings moiety
acts as a hydrophilic anchor at the liposomal mem-
brane surface. If the hydrogen bond-donating ability
of the OH groups is important for complex I inhibi-
tion, the acetylation of both OH groups in com-
pound II-A would have resulted in a marked de-
crease in potency, but this was not the case. Thus,
the present results along with our previous study [10]
do not support the model of active conformation of
acetogenins proposed by McLaughlin and colleagues.
However, we cannot necessarily exclude the validity
of their model for partitioning of acetogenins into the
liposomal membrane. In liposomal membranes, the
average location of THF and Q-lactone ring moieties
could be primarily determined by their hydrophobic-
ity [26].
In conclusion, a series of structure^activity studies
on acetogenin analogues performed in our laborato-
ry indicated that neither the natural Q-lactone ring
nor the 4-OH group are crucial for the potent inhib-
itory e¡ect. In addition, both the number of THF
rings and the stereochemistry surrounding the hy-
droxylated THF ring moiety are also not important
structural factors. Thus, the crucial structural fea-
tures of acetogenins required for the potent inhibi-
tion are unclear, except for the function of the alkyl
spacer. This is because either of the two ring moieties
(i.e. Q-lactone and THF) alone is not a reactive spe-
cies that directly interacts with the target site. There-
fore, we concluded that both ring moieties act in a
2 It should be noted that the hydrophilicities of ^OH and
^OCOCH3 groups, in terms of Z value in n-octanol/water system,
are comparable; i.e. 30.67 and 30.64, respectively (cf. C.
Hansch, and A. Leo, in: Substituent Constants for Correlation
Analysis in Chemistry and Biology, Wiley-Interscience, 1979,
New York).
3 Taking into consideration the amphiphilic character of di-
epomuricanin, the possibility that its apparent inhibition,
although very poor, was brought about by non-speci¢c perturba-
tion of the membrane (or the enzyme) structure due to high
concentrations cannot be excluded.
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cooperative manner on the enzyme with the support
of some speci¢c conformation of the spacer. The
present study indicated that there is an optimal
length of the alkyl spacer, i.e. approximately 13 car-
bon atoms. High polarity around the bis-THF rings
is important for the potent inhibitory e¡ect probably
because the putative target subunit of acetogenin
(PSST) is a hydrophilic protein.
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